Merus N.V. Announces Closing of Initial Public Offering

May 25, 2016

UTRECHT, the Netherlands, May 24, 2016 (GLOBE NEWSWIRE) --

Merus N.V. (“Merus”) (Nasdaq:MRUS) today announced the closing of its initial public offering of 5,500,000 common shares at an initial public offering price of $10.00 per share.  The shares began trading on The NASDAQ Global Market under the ticker symbol “MRUS” on May 19, 2016. All of the common shares in the offering were offered by Merus.  The net proceeds to Merus from the sale of shares in the offering are estimated to be approximately $47.3 million, after deducting the underwriting discounts and commissions and estimated offering expenses.

Citigroup Global Markets Inc. and Jefferies LLC acted as joint book-running managers for the offering, Guggenheim Securities, LLC acted as lead manager for the offering and Wedbush PacGrow acted as co-manager for the offering.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on May 18, 2016. The offering was made only by means of a prospectus.  Copies of the final prospectus relating to the offering may be obtained by contacting Citigroup by mail, c/o Broadridge Financial Solutions, at 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (800) 831-9146, or by email at prospectus@citi.com; or Jefferies LLC, by mail at 520 Madison Avenue, 2nd Floor, New York, New York 10022, Attention: Equity Syndicate Prospectus Department, by telephone at (877) 547-6340 or by email at prospectus_department@jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

Investor Relations
Argot Partners
Eliza Schleifstein – eliza@argotpartners.com

Home > News > Merus N.V. Announces Closing of Initial Public...

© 2024 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds